Targeting RAS–ERK signalling in cancer: promises and challenges

By A. Samatar, P. Poulikakos. Nature reviews. Drug discovery, 2014

1,026 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2ab4ac4f17c8f575d6bd82e610688d21db045d32

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. K. Rossman
2. C. Der
3. Michael Jendrusch
4. Zuguang Gu

In Oncology

1. K. Rossman
2. G. A. Hobbs
3. C. Der

Citations in the corpus

• Leveraging implicit knowledge in neural networks for functional dissection and engineering of proteins (2019, background): “ERK2 is a major signalling factor that is frequently deregulated across many cancer types 24 .”
• RAS isoforms and mutations in cancer at a glance (2016, background): “…delta) (Zimmermann et al., 2013), (iii) inhibitors of downstream effector signaling (e.g. RAF or PI3K effectors) (Fruman and Rommel, 2014; Samatar and Poulikakos, 2014), (iv) inhibitors of processes that support the increased metabolic needs of cancer cells (e.g. macropinocytosis,…”